Physician profile
Peter D Hino
NPI 1053407296
$13,701.11
in general payments reported to CMS, 2019-2025
37 companies · $2,850 in 2025
The $2,850 reported for 2025 was more than what 84% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,387 · 2020: $1,203 · 2021: $1,215 · 2022: $1,938 · 2023: $2,741 · 2024: $2,367 · 2025: $2,850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,859 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,858.70 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,004.17 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,563.34 | 2019-2025 | Winlevi, Ilumya |
| Galderma Laboratories, L.P. | $1,136.52 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Genzyme Corporation | $1,128.39 | 2019-2025 | |
| Leo Pharma INC. | $938.21 | 2019-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $907.77 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $731.05 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $719.83 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $593.30 | 2020-2025 | Dupixent, Libtayo |
| Mayne Pharma Commercial LLC | $445.23 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $408.57 | 2022-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $405.30 | 2019-2024 | Jublia, Arazlo, Cabtreo |
| Incyte Corporation | $371.28 | 2021-2025 | Opzelura |
| Amgen INC. | $332.51 | 2019-2025 | Otezla, Otezla |
| Almirall LLC | $327.70 | 2019-2025 | Seysara, Klisyri |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $286.82 | 2023-2025 | Zoryve |
| Pfizer INC. | $268.13 | 2019-2025 | |
| Journey Medical Corporation | $223.26 | 2020-2025 | |
| Ucb, INC. | $204.76 | 2020-2025 | Bimzelx |
| Dermavant Sciences, INC. | $106.58 | 2022-2024 | Vtama |
| Sandoz INC. | $78.71 | 2019-2020 | |
| Allergan, INC. | $75.20 | 2019-2021 | |
| Dermira, INC. | $69.18 | 2019-2021 | |
| Epi Health, LLC | $68.69 | 2020-2022 | |
| Celgene Corporation | $53.37 | 2019 | |
| Botanix Sb INC | $45.32 | 2025 | Sofdra |
| Organon LLC | $37.24 | 2025 | Vtama |
| Kyowa Kirin, INC. | $26.51 | 2024 | Poteligeo |
| Aclaris Therapeutics, INC. | $23.49 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $21.01 | 2023 | Valchlor |
| Integra Lifesciences Corporation | $18.74 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.83 | 2022 | |
| Nabriva Therapeutics, Plc | $15.47 | 2021 | |
| Mylan Pharmaceuticals INC. | $12.90 | 2019 | |
| Allegis Pharmaceuticals, LLC | $12.21 | 2023 | Spinosad |
| Icad, INC | $11.78 | 2021 | |
| Dusa Pharmaceuticals, INC. | $11.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Hino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.